Wang Yannan, Ma Zhonghui, Zheng Qizhe, Chu Yinglin, Hu Yunshuang, Liu Fei
Department of Stomatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Front Oncol. 2025 Mar 25;15:1486583. doi: 10.3389/fonc.2025.1486583. eCollection 2025.
To elucidate the association between allergy history and response to immune checkpoint inhibition (ICI) in recurrent or metastatic head and neck squamous cell carcinoma (RM/HNSCC).
Patients receiving ICI treatment for RM/HNSCC were retrospectively enrolled and classified into two groups based on their previous allergy history. The primary outcome variable assessed was the response to ICI.
A total of 157 patients were included, of whom 27 reported a history of allergies. In multivariate analysis, patients with allergies exhibited an odds ratio of 2.78 [95% confidence interval: 1.54-5.99], significantly surpassing that of the non-allergic group. Other independent predictors of ICI benefit included current smoking status and the primary tumor site being in the oropharynx or hypopharynx. Neither progression-free survival nor overall survival was adversely affected by prior allergy history or smoking status or HPV status or PD-L1 expression.
A prior history of allergies is associated with an enhanced response to immunotherapy in patients with RM/HNSCC.
阐明复发性或转移性头颈部鳞状细胞癌（RM/HNSCC）患者的过敏史与免疫检查点抑制（ICI）反应之间的关联。
对接受ICI治疗的RM/HNSCC患者进行回顾性纳入，并根据其既往过敏史分为两组。评估的主要结局变量是对ICI的反应。
共纳入157例患者，其中27例有过敏史。在多变量分析中，有过敏史的患者的优势比为2.78[95%置信区间：1.54 - 5.99]，显著高于非过敏组。ICI获益的其他独立预测因素包括当前吸烟状态以及原发肿瘤部位在口咽或下咽。无进展生存期和总生存期均未受到既往过敏史、吸烟状态、HPV状态或PD-L1表达的不利影响。
既往过敏史与RM/HNSCC患者对免疫治疗的反应增强有关。
